Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma. Miron B, Geynisman DM. Eur Urol 2022;82:374-376.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Miron B, Geynisman DM. Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma. Eur Urol 2022;82:374-376.
PMID: 35752503